Canada markets open in 32 minutes

Guardant Health, Inc. (GH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
17.96+0.27 (+1.53%)
At close: 04:00PM EDT
17.96 0.00 (0.00%)
Pre-Market: 08:18AM EDT

Guardant Health, Inc.

3100 Hanover Street
Palo Alto, CA 94304
United States
855 698 8887
https://guardanthealth.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full Time Employees1,768

Key Executives

NameTitlePayExercisedYear Born
Dr. Helmy Eltoukhy Ph.D.Co-Founder, Co-CEO & Chairman11.63kN/A1980
Dr. AmirAli Talasaz Ph.D.Co-CEO & Director11.18kN/A1980
Mr. Michael BellChief Financial Officer630.99kN/A1969
Mr. John G. SaiaChief Legal Officer & Corporate Secretary627.18kN/A1973
Dr. Craig Eagle M.D.Chief Medical Officer649.13kN/A1967
Mr. Christopher FreemanChief Commercial Officer630.39kN/A1974
Ms. Darya ChudovaChief Technology OfficerN/AN/AN/A
Mr. Kumud KaliaChief Information OfficerN/AN/A1966
Ms. Jennifer HigginsVice President of Public AffairsN/AN/AN/A
Ms. Terilyn Juarez MonroeChief People OfficerN/AN/A1967
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Corporate Governance

Guardant Health, Inc.’s ISS Governance QualityScore as of March 1, 2024 is 7. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.